House Dust Mite Allergy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our House Dust Mite Allergy – Drugs In Development, 2024 report and make more profitable business decisions.
House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose, and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants, and corticosteroids.
The House Dust Mite Allergy drugs in development market research report provide comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – House Dust Mite Allergy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of House Dust Mite Allergy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed House Dust Mite Allergy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of House Dust Mite Allergy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAdvagene Biopharma Co Ltd
ALK-Abello AS
Allergy Therapeutics Plc
Chula VRC
Genetic Immunity Inc
Probelte Pharma SA
Raphas Co Ltd
Roxall Medizin GmbH
Stallergenes Greer Ltd
Torii Pharmaceutical Co Ltd
Vanderbilt University Medical Center
Worg Pharmaceuticals Hangzhou Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more House Dust Mite Allergy reports